Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Currency in USD	2025
Operating Income	1.56 Billion
Income Before Tax	1.32 Billion
Income Tax Expense	0.00
Net Income	770.95 Million
Eps	1.79
Epsdiluted	1.78
Weighted Average Shs Out	429.80 Million
Weighted Average Shs Out Dil	564.46 Million
Research And Development Expenses	452.00 Million
Selling General And Administrative Expenses	N/A
Depreciation And Amortization	3.85 Million
Interest Expense	307.66 Million
Interest Income	33.59 Million
Net Interest Income	-274.07 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	N/A
Ebitda	1.56 Billion
Source	edgar
Ebit	1.63 Billion

Royalty Pharma plc Annual Reports (10-K)